Zhejiang Huahai Pharmaceutical

Name

Zhejiang Huahai Pharmaceutical

Legal name

Zhejiang Huahai Pharmaceutical Co., Ltd.

Website

https://en.huahaipharm.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals (APIs and Finished Dosage Forms)

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Active pharmaceutical ingredients
• Finished pharmaceutical products
• Contract manufacturing services
• Pharmaceutical packaging components
• Generic drug formulations

Headquarters

HQ city

Linhai

HQ country

China

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (APIs) & Intermediates: Manufacture and sale of validated APIs and intermediates including cardiovascular, anti-diabetic, anti-viral, and CNS products. Company is a leading global manufacturer with major export presence.
2. Finished Pharmaceutical Products: Finished dosage formulations including tablets, capsules, and injections for cardiovascular, central neurological, and anti-viral therapeutic areas. Products sold in China and international markets including US and EU.
3. Import and Export Trade Services: Trading platform for pharmaceutical raw materials covering intermediates, APIs, pharmaceutical excipients, cosmetics raw materials, animal health, and food supplements. Operates across multiple global markets.
4. Pharmaceutical Packaging: HDPE bottles and polypropylene caps for pharmaceuticals with US FDA Drug Master File approval. Child-resistant closure systems available.
5. Contract Manufacturing Organization (CMO) Services: Process development, formula development, clinical trial materials production, API manufacturing for chemical/biological medicines, intermediates, formulated products, and packaging services for third parties.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Core offering

Zhejiang Huahai Pharmaceutical manufactures and sells Active Pharmaceutical Ingredients (APIs) and intermediates (66+ products spanning cardiovascular, anti-diabetic, anti-epileptic, anti-viral, and anti-fungal therapeutic areas), finished dosage formulations (tablets, capsules, delayed-release, and lyophilized injections), pharmaceutical packaging components, and provides Contract Manufacturing Organization (CMO) and regulatory registration services to global pharmaceutical clients across approximately 200 countries and regions.

Product overview

Zhejiang Huahai Pharmaceutical is a vertically integrated pharmaceutical company founded in 1989, headquartered in Zhejiang Province, China. The company operates a multi-faceted business model comprising: (1) APIs & Intermediates manufacturing with 66+ validated products covering cardiovascular, anti-diabetic, anti-epileptic, anti-viral, and anti-fungal therapeutic areas; (2) Finished Pharmaceutical Products including tablets, capsules, and delayed-release formulations organized under Central Neurological, Cardiovascular, and Anti-viral categories; (3) Pharmaceutical Packaging division producing FDA-approved containers and closures; (4) CMO Services offering contract manufacturing with 3,000+ tons/year API capacity and 20 billion units/year solid dosage capacity; (5) Registration and Declaration Services providing regulatory submission support for global markets; and (6) Global distribution through subsidiaries including Solco Healthcare (US), Huahai (Europe), Huahai Japan, and Shanghai Huaota Biopharmaceutical (biologics). The company serves approximately 200 countries and regions with major production facilities in Linhai, Zhejiang and Nantong, Jiangsu.

Differentiator

Problem solved

Functional benefit

Products and services

• APIs & Intermediates

Quantifiable outcome

• Ranked No. 1 among top 10 export enterprises in China's generic medicines industry
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

21 partnerships are on record, tiered major, core and minor.

• AlmirallmajorStrategic or Co-development Partner · 27 March 2026Collaboration and licensing agreement with Shanghai Huaota Biopharmaceutical (subsidiary of Zhejiang Huahai Pharmaceutical) to develop a monoclonal antibody candidate for multiple therapeutic indications in medical dermatology. Huaota leads early-stage research and initial clinical development in China while Almirall retains global development and commercialization rights outside China. Deal potentially worth up to USD 340 million in upfront payments, development and commercial milestones, and tiered royalties.
• China Pharmaceutical UniversitycoreStrategic or Co-development Partner · 20 September 2019Signed cooperative project for R&D center of innovative drugs and high-end preparations. The center focuses on discovery and confirmation of new drug targets, research and evaluation of innovative drugs and high-end preparations, and research and development of drug crystals.
• Shanghai Tongji UniversitycoreStrategic or Co-development Partner · 14 January 2015Co-built Institute of Environmental Protection and Engineering Research and Environmental Protection Postdoctoral Workstation. Part of multi-level R&D cooperation with over 20 renowned scientific research institutions and colleges/universities.
• ONCOBIOLOGICS (US)majorStrategic or Co-development Partner · 6 May 2013Signed agreement for strategic cooperation in biological medicine with US biopharma company ONCOBIOLOGICS. First program successfully put into trial production in Shanghai Huaota Biopharm Co., Ltd.
• South Korean EutilexmajorStrategic or Co-development PartnerStrategic cooperation with South Korean Eutilex for biopharmaceutical development. Company also invested in shares of Eutilex in Korea in 2017.
• NovartiscoreStrategic or Co-development PartnerExecutives from 18 pharmaceutical giants including Novartis visited Huahai, exchanging with Chen Baohua (general manager), Chen Qimao (deputy general manager), and Wang Hai (senior vice president). Strategic relationship with major global pharma.
• Tasly Pharmaceutical GroupminorStrategic or Co-development PartnerFramework Agreement for Strategic Cooperation between Tasly Pharmaceutical Group Co., Ltd. and Huahai US Inc.
• Tianjin Pharmaceutical Group Co., Ltd.minorStrategic or Co-development PartnerFramework agreement for strategic cooperation signed with Tianjin Pharmaceutical Group Co., Ltd.
• Enze MedicalminorStrategic or Co-development PartnerSigned agreement for strategic cooperation with Enze Medical.
• LP PharmaminorStrategic or Co-development PartnerStrategic cooperation agreement signed with LP Pharma and Zhejiang Pharmaceutical Co., Ltd.
• Shouguang Fukang Pharmaceutical Co., Ltd.minorStrategic or Co-development PartnerFramework agreement for strategic cooperation signed with Shouguang Fukang Pharmaceutical Co., Ltd.
• Apeloa Pharmaceutical (Zhejiang)minorStrategic or Co-development PartnerZhejiang Apeloa Pharmaceutical signed framework agreement for strategic cooperation with Huahai (USA) Company.
• Liu Changxiao (Academician, Chinese Academy of Engineering)coreStrategic or Co-development PartnerCooperated with academician Liu Changxiao to build an academician workstation.
• Shanghai Institute of Organic Chemistry, Chinese Academy of SciencescoreStrategic or Co-development PartnerJoint Research Center established for collaborative R&D.
• Academy of Military Medical SciencesmajorStrategic or Co-development PartnerDevelopment of innovative drug Hydroxypiperone Hydrochloride with academy. Successfully transferred technologies for Class-1.1 new antidepressant drug Hydroxypiperone Hydrochloride Tablets.
• Dali UniversityminorStrategic or Co-development PartnerAgreement for Strategic Enterprise-University-Research Cooperation between Universities and Enterprises.
• Taizhou Vocational and Technical CollegecoreStrategic or Co-development PartnerStrategic signing ceremony to build Taizhou Vocational and Technical College Hua Hai College to transport professional and skilled personnel for pharmaceutical industry.
• Zhejiang University of TechnologycoreStrategic or Co-development PartnerCollege of Pharmaceutical Science of Zhejiang University of Technology and Huahai Pharmaceutical jointly held ceremony to launch training base. Received Most Popular Employer Award from ZUT.
• Zhejiang UniversityminorStrategic or Co-development PartnerSchool-enterprise cooperation with Zhejiang University, sending business backbones for further education promotion and joint postgraduate training.
• Fudan UniversityminorStrategic or Co-development PartnerSchool-enterprise cooperation with Fudan University for postgraduate training.
• Novartis International Pharmaceutical Co., Ltd.coreStrategic or Co-development PartnerSigned strategic agreement with Novartis International Pharmaceutical Co., Ltd. to further promote internationalization process with pharmaceutical giants.

Scale indicators15 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• Dr. Reddy's Laboratories: Indian vertically integrated generic pharmaceutical and API manufacturer with comparable global generics platform, ANDA portfolio, and US distribution footprint (similar to Huahai's Solco and Huahai US Inc.).
• Aurobindo Pharma: Large Indian generic and API manufacturer with a broad cardiovascular/CNS portfolio and significant US finished-dose presence, directly competing in the same molecules and customer base as Huahai.
• Lupin Limited: Indian pharma company with integrated API-to-finished-dose operations and a strong US generics franchise (cardiovascular, CNS, anti-infective) — overlapping therapeutic mix and geographic channels.
• Apotex Inc. Canadian-based generic pharmaceutical manufacturer producing APIs and finished dosage forms across cardiovascular and CNS, with significant US market exposure similar to Huahai.
• Alembic Pharmaceuticals: India-based vertically integrated generic pharma with strong API capabilities and US ANDA portfolio across cardiovascular, anti-infective, and CNS — comparable therapeutic and geographic overlap.
• Divi's Laboratories: Indian API manufacturer specializing in custom synthesis and generics with similar large-scale API capacity and export focus to regulated markets, directly comparable to Huahai's API business.

Broad incumbents

• Teva Pharmaceutical Industries: Global generic pharmaceutical giant with API manufacturing and broad CNS/cardiovascular franchise; not a direct API supplier peer but operates in the same generic value chain Huahai serves.
• Viatris (Mylan): Major global generic finished-dose manufacturer with cardiovascular and CNS portfolios, often a buyer of APIs from companies like Huahai while also competing in finished dosage in some markets.

Regional players

• Shanghai Pharmaceuticals Holding: Major Chinese pharmaceutical group combining API manufacturing, finished dosage, and distribution. Comparable vertically integrated model within the same domestic Chinese market.
• CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharmaceutical company with API and finished-dose operations across cardiovascular and CNS, providing a domestic comparable for scale and product mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhejiang Huahai Pharmaceutical